Paul Brennan
paulnbrennan.bsky.social
Paul Brennan
@paulnbrennan.bsky.social
Academic Hepatologist, MASLD, epidemiology and public health and policy
Rugby enthusiast 🏉 and odd heavy guitar 🎸 riff
Irish☘️ 🇮🇪 in exile in Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿
Reposted by Paul Brennan
The 🌎 burden of #MASH is staggering: 5.3% of adults face higher risks of cirrhosis, liver cancer & other complications as fibrosis progresses.
our latest study on MAESTRO-NASH resmetirom data & its real-world implications post-FDA approval www.nature.com/articles/s44... #SLDsummit
January 23, 2025 at 11:14 AM
Thanks for highlighting our paper @dufourjf.bsky.social! Challenging to undertake these trials in ACLD but hopefully offers some potential utility, more from this cohort to come in our long term follow up analysis this summer 🤞
January 13, 2025 at 9:03 PM
My take away is that immediately pre- surgery the Post-TIPSS group had worse MELD composites, whilst they had good PSM controlling at time point 6 months before, they were clearly less robust at time of intervention. What about matching with similar non-TIPSS MELD controls at time of op?
January 6, 2025 at 10:59 PM